Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

A Kuendgen, M Lauseker, AF List, P Fenaux, AA Giagounidis, NA Brandenburg, J Backstrom, A Glasmacher, J Hasford, U Germing

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1072-1079
Number of pages8
JournalLeukemia
Volume27
Issue number5
DOIs
Publication statusPublished - 2013
Externally publishedYes

Cite this